ASND - Conference and earnings call announcements

COPENHAGEN, Denmark, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that company executives will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time in New York, New York. A live webcast of the presentation will be available via the Investors & News section of the Ascendis Pharma website at investors.ascendispharma.com. A webcast replay will also be available on this website shortly after conclusion of the event for 30 days. About Ascendis Pharma A/SAscendis Pharma is a global biopharmaceutical company focused on applying our i

COPENHAGEN, Denmark, March 02, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that company executives will participate in a virtual fireside chat at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026, at 11:10 a.m. Eastern Time / 8:10 a.m. Pacific Time in Boston, Massachusetts. A live webcast of the presentation will be available via the Investors & News section of the Ascendis Pharma website at investors.ascendispharma.com. A webcast replay will also be available on this website shortly after conclusion of the event for 30 days. About Ascendis Pharma A/S Ascendis Pharma is a global biopharmaceutical company focused on applying our innova

COPENHAGEN, Denmark, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that company executives will participate in the 44th Annual J.P. Morgan Healthcare Conference and provide a business update on Monday, January 12, 2026, at 10:30 a.m. Eastern Time / 7:30 a.m. Pacific Time in San Francisco, California. A live webcast of the presentation will be available via the Investors & News section of the Ascendis Pharma website at investors.ascendispharma.com. A webcast replay will also be available on this website shortly after conclusion of the event for 30 days. About Ascendis Pharma A/SAscendis Pharma is a global biopharmaceutical company focused on applying

COPENHAGEN, Denmark, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that company executives will participate in a fireside chat at the 2025 Wells Fargo Healthcare Conference on Wednesday, September 3, 2025, at 8:00 a.m. Eastern Time / 5:00 a.m. Pacific Time in Boston, Massachusetts. A live webcast of the presentation will be available via the Investors & News section of the Ascendis Pharma website at investors.ascendispharma.com. A webcast replay will also be available on this website shortly after conclusion of the event for 30 days. About Ascendis Pharma A/S Ascendis Pharma is a global biopharmaceutical company focused on applying our innovative Tra

COPENHAGEN, Denmark, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that company executives will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 11:10 a.m. Eastern Time / 8:10 a.m. Pacific Time in Boston, Massachusetts. A live webcast of the presentation will be available via the Investors & News section of the Ascendis Pharma website at investors.ascendispharma.com. A webcast replay will also be available on this website shortly after conclusion of the event for 30 days. About Ascendis Pharma A/SAscendis Pharma is applying its innovative TransCon technology platform to build a leading, f

COPENHAGEN, Denmark, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that company executives will participate in the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 11:15 a.m. Eastern Time / 8:15 a.m. Pacific Time in San Francisco, California. A live webcast of the presentation will be available via the Investors & News section of the Ascendis Pharma website at investors.ascendispharma.com. A webcast replay will also be available on this website shortly after conclusion of the event for 30 days. About Ascendis Pharma A/SAscendis Pharma is applying its innovative TransCon technology platform to build a leading, fully integr

COPENHAGEN, Denmark, June 04, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that company executives will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024, at 8:00 a.m. ET in Miami, Florida. A live webcast of the fireside chat will be available via the Investors & News section of the Ascendis Pharma website at investors.ascendispharma.com. A webcast replay will also be available on this website shortly after conclusion of the event for 30 days. About Ascendis Pharma A/SAscendis Pharma is applying its innovative TransCon technology platform to build a leading, fully integrated biopharma compa

COPENHAGEN, Denmark, March 04, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that company executives will participate in a fireside chat at the Leerink Partners Global Biopharma Conference 2024 on Monday, March 11, 2024 at 2:00 p.m. ET in Miami, Florida. A live webcast of the fireside chat will be available via the Investors & News section of the Ascendis Pharma website at investors.ascendispharma.com. A webcast replay will also be available on this website shortly after conclusion of the event for 30 days. About Ascendis Pharma A/SAscendis Pharma is applying its innovative TransCon technology platform to build a leading, fully integrated biopharma co

COPENHAGEN, Denmark, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that company executives will participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference. Details: EventOppenheimer 34th Annual Healthcare Life Sciences ConferenceLocationVirtualDateTuesday, February 13, 2024Time4:00 p.m. Eastern Time / 1:00 p.m. Pacific Time A live webcast of the event will be available via the Investors & News section of the Ascendis Pharma website at investors.ascendispharma.com. A webcast replay will also be available on this website shortly after conclusion of the event for 30 days. About Ascendis Pharma A/SAscendis Pharma is applying its inno

COPENHAGEN, Denmark, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that Jan Mikkelsen, President & Chief Executive Officer, Scott Smith, Executive Vice President & Chief Financial Officer, and Kennett Sprogøe, Ph.D., Executive Vice President, Head of Research & Product Development, will participate in the 42nd Annual J.P. Morgan Healthcare Conference. Details: Event42nd Annual J.P. Morgan Healthcare ConferenceLocationSan Francisco, CADateMonday, January 8, 2024Time12:00-12:40 p.m. Eastern Time / 9:00-9:40 a.m. Pacific Time   A live webcast of the event will be available via the Investors & News section of the Ascendis Pharma website at investors.asce

COPENHAGEN, Denmark, June 07, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that Jan Mikkelsen, President & Chief Executive Officer, and Scott Smith, Executive Vice President & Chief Financial Officer, will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference on Tuesday, June 13. Details: EventGoldman Sachs 44th Annual Global Healthcare ConferenceLocationDana Point, CADateTuesday, June 13, 2023Time12:20 p.m. Eastern Time / 9:20 a.m. Pacific Time A live webcast of the event will be available via the Investors & News section of the Ascendis Pharma website at https://investors.ascendispharma.com. A webcast replay will a

COPENHAGEN, Denmark, May 03, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that Jan Mikkelsen, President & Chief Executive Officer, and Scott Smith, Executive Vice President & Chief Financial Officer, will participate in a virtual fireside chat at the BofA Securities 2023 Health Care Conference on Tuesday, May 9. Details: EventBofA Securities 2023 Health Care ConferenceLocationLas Vegas, NVDateTuesday, May 9, 2023Time11:40 a.m. Eastern Time / 8:40 a.m. Pacific Time   A live webcast of the event will be available via the Investors & News section of the Ascendis Pharma website at https://investors.ascendispharma.com. A webcast replay will also be available o

COPENHAGEN, Denmark, March 10, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that Jan Mikkelsen, President & Chief Executive Officer, and Scott Smith, Executive Vice President & Chief Financial Officer, will participate in a virtual fireside chat at the Oppenheimer 33rd Annual Healthcare Conference on Wednesday, March 15. Details: EventOppenheimer 33rd Annual Healthcare ConferenceLocationVirtualDateWednesday, March 15, 2023Time12:00-12:30 p.m. Eastern Time / 9:00-9:30 a.m. Pacific Time   A live webcast of the event will be available via the Investors & News section of the Ascendis Pharma website at https://investors.ascendispharma.com. A webcast re

COPENHAGEN, Denmark, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) announced today that the Company is scheduled to present at the 41st Annual J.P. Morgan Healthcare Conference. Details: Event41st Annual J.P. Morgan Healthcare ConferenceLocationSan Francisco, CADateMonday, January 9, 2023Time12:00-12:40 p.m. Eastern Time / 9:00-9:40 a.m. Pacific Time A live webcast of the event will be available via the Investors & News section of the Ascendis Pharma website at https://investors.ascendispharma.com. A webcast replay will also be available on this website shortly after conclusion of the event for 30 days. About Ascendis Pharma A/SAscendis Pharma is applying its innova

COPENHAGEN, Denmark, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) announced today that the company is scheduled to participate in the 5th Annual Evercore ISI HealthCONx Conference. Company executives will participate in a virtual fireside chat hosted by Evercore. Details: Event5th Annual Evercore ISI HealthCONx ConferenceLocationVirtualDateThursday, December 1, 2022Time1:00-1:20 p.m. Eastern Time / 10:00-10:20 a.m. Pacific Time A live webcast of the event will be available on the Investors & News section of the Ascendis Pharma website at https://investors.ascendispharma.com. A webcast replay will also be available on this website shortly after conclusion of the even

COPENHAGEN, Denmark, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) announced today that the company is scheduled to participate in three upcoming investor conferences in September. Details: EventCiti's 17th Annual BioPharma ConferenceLocationBoston, MADateWednesday, September 7, 2022Time3:30-4:15 p.m. Eastern Time / 12:30-1:15 p.m. Pacific TimeSpeaker(s)Scott Smith, Senior Vice President, Chief Financial Officer Event2022 Wells Fargo Healthcare ConferenceLocationBoston, MADateThursday, September 8, 2022Time8:35-9:05 a.m. Eastern Time / 5:35-6:05 a.m. Pacific TimeSpeaker(s)Scott Smith, Senior Vice President, Chief Financial Officer EventMorgan Stanley 20th Annual

COPENHAGEN, Denmark, May 09, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) announced today that the company is scheduled to attend the BofA Securities 2022 Healthcare Conference. Company executives will participate in a fireside chat hosted by BofA on Thursday, May 12. Details EventBofA Securities 2022 Healthcare ConferenceLocationLas Vegas, NVDateThursday, May 12, 2022Time1:40-2:10 p.m. Eastern Time /10:40-11:10 a.m. Pacific Time A live webcast of the event will be available on the Investors and News section of the Ascendis Pharma website at www.ascendispharma.com. A webcast replay will be available on this website shortly after conclusion of the event for 30 days. About As

COPENHAGEN, Denmark, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that the Company is scheduled to participate in the 11th Annual SVB Leerink Global Healthcare Conference. Company executives will participate in a virtual fireside chat hosted by SVB Leerink. Details Event11th Annual SVB Leerink Global Healthcare ConferenceLocationVirtualDateWednesday, February 16, 2022Time3:00-3:30 p.m. Eastern Time A live webcast of the event will be available on the Investors and News section of the Ascendis Pharma website at https://ascendispharma.com. A webcast replay will be available on the site shortly after conclusion of the event and will stay available for 3

COPENHAGEN, Denmark, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that the Company is scheduled to participate in the upcoming 40th Annual J.P. Morgan Healthcare Conference. Company executives will provide a business overview and update on the company's pipeline programs. Details Event40th Annual J.P. Morgan Healthcare ConferenceLocationVirtualDate Monday, January 10, 2022Time3:00 p.m.-3:40 p.m. Eastern Time A live webcast of the event will be available on the Investors & News section of the Ascendis Pharma website at https://ascendispharma.com. A webcast replay will be available on the site shortly after conclusion of the event and will stay ava

COPENHAGEN, Denmark, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that the Company is scheduled to participate in the Evercore ISI 4th Annual HealthCONx Conference. Company executives will participate in a virtual fireside chat hosted by Evercore ISI. Details EventEvercore ISI 4th Annual HealthCONx ConferenceLocationVirtualDateWednesday, December 1, 2021Time3:55-4:15 p.m. Eastern Time A live audio webcast of the presentation will be available on the Investors & News section of the Company's website at http://www.ascendispharma.com/. A webcast replay will be available on the Company's website shortly after conclusion of the event for 30 days. About A

– 58 subjects continue in the open-label extension study for TransCon PTH – COPENHAGEN, Denmark, May 10, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to create product candidates that address unmet medical needs, today announced preliminary 58-week results from the continuing open-label extension (OLE) portion of the PaTH Forward Trial, a global phase 2 trial evaluating the safety, tolerability, and efficacy of its investigational product candidate TransCon PTH in adult subjects with hypoparathyroidism (HP). "Today we announced results which demonstrated, after one year of treatment, that Trans